Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Viridian Therapeutics initiated with a Buy at H.C. Wainwright » 06:09
12/01/22
12/01
06:09
12/01/22
06:09
VRDN

Viridian Therapeutics

$25.22 /

+2.37 (+10.37%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Douglas Tsao initiated coverage of Viridian Therapeutics with a Buy rating and $35 price target. The analyst says the company is well positioned for leadership in the over $2B thyroid eye disease market. He think Viridian's portfolio of IGF-1R antagonist mAbs offers competitive advantages which give it an opportunity to challenge Horizon's Tepezza.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$25.22 /

+2.37 (+10.37%)

VRDN Viridian Therapeutics
$25.22 /

+2.37 (+10.37%)

10/14/22 Evercore ISI
Viridian Therapeutics added to 'TAP Outperform' list at Evercore ISI
08/16/22 B. Riley
Viridian Therapeutics price target raised to $40 from $25 at B. Riley
08/15/22 Evercore ISI
Viridian Therapeutics price target raised to $50 from $40 at Evercore ISI
06/23/22 B. Riley
B. Riley starts Viridian Therapeutics at Buy with $25 price target
VRDN Viridian Therapeutics
$25.22 /

+2.37 (+10.37%)

  • 17
    Aug
VRDN Viridian Therapeutics
$25.22 /

+2.37 (+10.37%)

Over a week ago
Earnings
Viridian Therapeutics reports Q3 EPS (86c), consensus (95c) » 07:17
11/14/22
11/14
07:17
11/14/22
07:17
VRDN

Viridian Therapeutics

$20.52 /

+0.73 (+3.69%)

Reports Q3 revenue…

Reports Q3 revenue $1.195M, consensus $260,000. "The positive VRDN-001 clinical data reported today reinforces our conviction in the potential for VRDN-001 to deliver improved care for patients suffering with TED. Across all efficacy measures, VRDN-001 continues to deliver a rapid, compelling, and clinically meaningful improvement for patients after just two infusions," said Jonathan Violin, Ph.D., President and CEO of Viridian Therapeutics. "We have continued our rapid momentum with the recent initiation of our Phase 3 THRIVE program as we accelerate our portfolio of IV and SC TED assets towards approval."

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$20.52 /

+0.73 (+3.69%)

VRDN Viridian Therapeutics
$20.52 /

+0.73 (+3.69%)

10/14/22 Evercore ISI
Viridian Therapeutics added to 'TAP Outperform' list at Evercore ISI
08/16/22 B. Riley
Viridian Therapeutics price target raised to $40 from $25 at B. Riley
08/15/22 Evercore ISI
Viridian Therapeutics price target raised to $50 from $40 at Evercore ISI
06/23/22 B. Riley
B. Riley starts Viridian Therapeutics at Buy with $25 price target
VRDN Viridian Therapeutics
$20.52 /

+0.73 (+3.69%)

  • 17
    Aug
VRDN Viridian Therapeutics
$20.52 /

+0.73 (+3.69%)

Over a month ago
Hot Stocks
Viridian Therapeutics presents data from ongoing VRDN-001 Phase 1/2 trial » 15:51
10/23/22
10/23
15:51
10/23/22
15:51
VRDN

Viridian Therapeutics

$19.99 /

+0.55 (+2.83%)

Viridian Therapeutics…

Viridian Therapeutics presented proof-of-concept data from the 10 mg/kg cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease. These data, as well as new in vitro data further characterizing and differentiating the pharmacological profile of VRDN-001, were included as part of three late-breaking poster presentations at the American Thyroid Association 91st Annual Meeting. The abstract describing new in vitro data on the distinct anti-IGF-1R profile of VRDN-001 was also selected as an oral highlighted late breaking presentation. ATA Poster #535: "VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor Receptor-1 (IGF-1R) for Thyroid Eye Disease (TED): Phase 1/2 Proof of Concept in Patients with TED" presents proof-of-concept data from the first cohort of patients with active TED treated in the ongoing Phase 1/2 clinical trial. In this cohort, a total of 8 patients were randomized to receive two infusions of 10 mg/kg dose of VRDN-001 or placebo intravenously; 6 patients received VRDN-001 and 2 patients received placebo. In patients receiving VRDN-001, proptosis response was achieved by 83% of patients, with a mean reduction of 2.4 mm from baseline. Clinical Activity Score of 0 or 1 was achieved by 83% of patients, with a mean reduction of 4.3 points from baseline. Complete resolution of diplopia was achieved by 75% of patients who presented with diplopia at baseline. VRDN-001 demonstrated a favorable safety and tolerability profile with no reported SAEs, no hyperglycemia, and no infusion reactions. ATA Poster #568: "VRDN-001, A Potent and Selective Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody for Thyroid Eye Disease (TED): Phase 1 Safety and Pharmacodynamic Results in Healthy Volunteers" presents full safety and pharmacodynamic data from the completed healthy volunteer portion of the ongoing Phase 1/2 trial of VRDN-001. A total of 13 subjects were randomized to receive two infusions of either 3, 10, or 20 mg/kg dose of VRDN-001 or placebo. Twelve subjects completed the trial; one of the subjects in the 20 mg/kg group withdrew for personal reasons after the first infusion and was followed through Day 35. Plasma levels of IGF-1, a biomarker for IGF-1R antagonism, increased five- to seven-fold above baseline indicating maximal target engagement at all doses. All doses studied were generally safe and well tolerated, with no cases of hearing impairment or treatment related hyperglycemia and no infusion reactions. ATA Poster #132: "VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Development for Thyroid Eye Disease (TED), Binds to a Distinct Epitope from Teprotumumab" presents preclinical data from in vitro studies of VRDN-001.The data show that VRDN-001 binds the same region of the IGF-1R as teprotumumab but engages a distinct epitope. This difference in binding translated to differences in functional effects: unlike the anti-IGF-1R antibody teprotumumab, which incompletely antagonized IGF-1R function, VRDN-001 fully antagonized ligand binding, receptor autophosphorylation, and downstream signaling. These pharmacological differences may provide a mechanistic basis for the initial data reported from the ongoing VRDN-001 Phase 1/2 study, including the pharmacodynamic responses in the healthy volunteer cohort presented in Poster #568 and favorable clinical responses seen in TED patients as presented in Poster #535. The company remains on track to present additional updates from the VRDN-001 Phase 1/2 study this quarter. These updates will include top-line data for the 20 mg/kg cohort of the ongoing Phase 1/2 trial of VRDN-001 in TED, followed later this quarter by top-line data from the currently enrolling 3 mg/kg cohort. This ongoing trial is evaluating two infusions of VRDN-001, three weeks apart, with efficacy measured six weeks after the first dose. Each dose is evaluated in a cohort of eight patients, randomized so that six patients receive VRDN-001 and two patients receive placebo. The first cohort evaluated a dose of 10 mg/kg, with initial clinical data reported on August 15, 2022. The Company expects to initiate the pivotal program for VRDN-001 by the end of 2022. This quarter the company also will report final pharmacokinetic and pharmacodynamic data from Viridian's first-in-human trial of VRDN-002, a half-life extended IGF-1R antibody, which build upon the recently presented interim results. The Company expects data from a proof-of-concept trial of subcutaneously administered VRDN-002 in the second half of 2023.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$19.99 /

+0.55 (+2.83%)

VRDN Viridian Therapeutics
$19.99 /

+0.55 (+2.83%)

10/14/22 Evercore ISI
Viridian Therapeutics added to 'TAP Outperform' list at Evercore ISI
08/16/22 B. Riley
Viridian Therapeutics price target raised to $40 from $25 at B. Riley
08/15/22 Evercore ISI
Viridian Therapeutics price target raised to $50 from $40 at Evercore ISI
06/23/22 B. Riley
B. Riley starts Viridian Therapeutics at Buy with $25 price target
VRDN Viridian Therapeutics
$19.99 /

+0.55 (+2.83%)

  • 17
    Aug
VRDN Viridian Therapeutics
$19.99 /

+0.55 (+2.83%)

Recommendations
Viridian Therapeutics added to 'TAP Outperform' list at Evercore ISI » 10:05
10/14/22
10/14
10:05
10/14/22
10:05
VRDN

Viridian Therapeutics

$21.73 /

+0.58 (+2.74%)

Evercore ISI analyst…

Evercore ISI analyst Gavin Clark-Gartner is adding Viridian Therapeutics to the firm's "Tactical Outperform" list ahead of data updates expected to come this quarter, including 20 mg/kg data to come at the ATA medical meeting next weekend. He has been hearing from investors that positioning is "generally conservative" heading into these updates and he agrees, which offers "another good entry point for investors" given his view that positive data could drive about 50% upside to shares. Clark-Gartner has an Outperform; rating and $50 price target on Viridian shares.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$21.73 /

+0.58 (+2.74%)

VRDN Viridian Therapeutics
$21.73 /

+0.58 (+2.74%)

08/16/22 B. Riley
Viridian Therapeutics price target raised to $40 from $25 at B. Riley
08/15/22 Evercore ISI
Viridian Therapeutics price target raised to $50 from $40 at Evercore ISI
06/23/22 B. Riley
B. Riley starts Viridian Therapeutics at Buy with $25 price target
06/23/22 B. Riley
Viridian Therapeutics initiated with a Buy at B. Riley
VRDN Viridian Therapeutics
$21.73 /

+0.58 (+2.74%)

  • 17
    Aug
VRDN Viridian Therapeutics
$21.73 /

+0.58 (+2.74%)

Syndicate
Viridian Therapeutics files automatic mixed securities shelf  16:07
09/09/22
09/09
16:07
09/09/22
16:07
VRDN

Viridian Therapeutics

$22.67 /

+0.63 (+2.86%)

 
ShowHide Related Items >><<
VRDN Viridian Therapeutics
$22.67 /

+0.63 (+2.86%)

VRDN Viridian Therapeutics
$22.67 /

+0.63 (+2.86%)

08/16/22 B. Riley
Viridian Therapeutics price target raised to $40 from $25 at B. Riley
08/15/22 Evercore ISI
Viridian Therapeutics price target raised to $50 from $40 at Evercore ISI
06/23/22 B. Riley
B. Riley starts Viridian Therapeutics at Buy with $25 price target
06/23/22 B. Riley
Viridian Therapeutics initiated with a Buy at B. Riley
VRDN Viridian Therapeutics
$22.67 /

+0.63 (+2.86%)

  • 17
    Aug
  • 21
    Sep
VRDN Viridian Therapeutics
$22.67 /

+0.63 (+2.86%)

Over a quarter ago
Hot Stocks
Viridian Therapeutics announces inducement grants under Nasdaq listing rule » 08:13
09/02/22
09/02
08:13
09/02/22
08:13
VRDN

Viridian Therapeutics

$21.23 /

-0.98 (-4.41%)

Viridian Therapeutics…

Viridian Therapeutics announced that a majority of the independent directors serving on the Compensation Committee of the Company's Board of Directors approved the grant of stock options to purchase an aggregate of 103,000 shares of the Company's common stock to three new employees on September 1, 2022. The Inducement Grants have been granted outside of the Company's Amended and Restated 2016 Equity Incentive Plan but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian's common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to continued employment through the applicable vesting dates.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$21.23 /

-0.98 (-4.41%)

VRDN Viridian Therapeutics
$21.23 /

-0.98 (-4.41%)

08/16/22 B. Riley
Viridian Therapeutics price target raised to $40 from $25 at B. Riley
08/15/22 Evercore ISI
Viridian Therapeutics price target raised to $50 from $40 at Evercore ISI
06/23/22 B. Riley
B. Riley starts Viridian Therapeutics at Buy with $25 price target
06/23/22 B. Riley
Viridian Therapeutics initiated with a Buy at B. Riley
VRDN Viridian Therapeutics
$21.23 /

-0.98 (-4.41%)

  • 17
    Aug
  • 21
    Sep
VRDN Viridian Therapeutics
$21.23 /

-0.98 (-4.41%)

Syndicate
Viridian Therapeutics 9.628M share Secondary priced at $23.50 » 06:06
08/17/22
08/17
06:06
08/17/22
06:06
VRDN

Viridian Therapeutics

$25.43 /

+3.49 (+15.91%)

The deal size was…

The deal size was increased to $270M in common stock from $175M in common stock. Jefferies, SVB Securities and Evercore ISI acted as joint book running managers for the offering.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$25.43 /

+3.49 (+15.91%)

VRDN Viridian Therapeutics
$25.43 /

+3.49 (+15.91%)

08/16/22 B. Riley
Viridian Therapeutics price target raised to $40 from $25 at B. Riley
08/15/22 Evercore ISI
Viridian Therapeutics price target raised to $50 from $40 at Evercore ISI
06/23/22 B. Riley
B. Riley starts Viridian Therapeutics at Buy with $25 price target
06/23/22 B. Riley
Viridian Therapeutics initiated with a Buy at B. Riley
VRDN Viridian Therapeutics
$25.43 /

+3.49 (+15.91%)

  • 17
    Aug
  • 21
    Sep
VRDN Viridian Therapeutics
$25.43 /

+3.49 (+15.91%)

Recommendations
Viridian Therapeutics price target raised to $40 from $25 at B. Riley » 09:28
08/16/22
08/16
09:28
08/16/22
09:28
VRDN

Viridian Therapeutics

$21.94 /

+7.06 (+47.45%)

B. Riley analyst Kalpit…

B. Riley analyst Kalpit Patel raised the firm's price target on Viridian Therapeutics to $40 from $25 and keeps a Buy rating on the shares after the first look at VRDN-001 data in TED patients came in above expectations. While he acknowledges that these results are from a small sample size, VRDN-001 is delivering signals of potentially enhanced efficacy relative to historical observations with Tepezza, said Patel, who raised his view on the odds of success for VRDN-001 to 65% from 45%.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$21.94 /

+7.06 (+47.45%)

VRDN Viridian Therapeutics
$21.94 /

+7.06 (+47.45%)

08/15/22 Evercore ISI
Viridian Therapeutics price target raised to $50 from $40 at Evercore ISI
06/23/22 B. Riley
B. Riley starts Viridian Therapeutics at Buy with $25 price target
06/23/22 B. Riley
Viridian Therapeutics initiated with a Buy at B. Riley
11/18/21 SVB Securities
Viridian Therapeutics initiated with an Outperform at SVB Leerink
VRDN Viridian Therapeutics
$21.94 /

+7.06 (+47.45%)

  • 17
    Aug
  • 21
    Sep
VRDN Viridian Therapeutics
$21.94 /

+7.06 (+47.45%)

Syndicate
Viridian files to sell $175 million of common stock and series B prefered stock » 16:13
08/15/22
08/15
16:13
08/15/22
16:13
VRDN

Viridian Therapeutics

$21.93 /

+7.05 (+47.38%)

Jefferies, SVB Securities…

Jefferies, SVB Securities and Evercore ISI are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$21.93 /

+7.05 (+47.38%)

VRDN Viridian Therapeutics
$21.93 /

+7.05 (+47.38%)

08/15/22 Evercore ISI
Viridian Therapeutics price target raised to $50 from $40 at Evercore ISI
06/23/22 B. Riley
B. Riley starts Viridian Therapeutics at Buy with $25 price target
06/23/22 B. Riley
Viridian Therapeutics initiated with a Buy at B. Riley
11/18/21 SVB Securities
Viridian Therapeutics initiated with an Outperform at SVB Leerink
VRDN Viridian Therapeutics
$21.93 /

+7.05 (+47.38%)

  • 21
    Sep
VRDN Viridian Therapeutics
$21.93 /

+7.05 (+47.38%)

On The Fly
What You Missed On Wall Street On Monday » 16:10
08/15/22
08/15
16:10
08/15/22
16:10
WMT

Walmart

$132.59 /

+0.34 (+0.26%)

, PARA

Paramount

$26.57 /

+0.365 (+1.39%)

, DIS

Disney

$124.25 /

+2.695 (+2.22%)

, CMCSA

Comcast

$40.55 /

+0.56 (+1.40%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

, APP

AppLovin

$33.45 /

-2.895 (-7.97%)

, IS

ironSource

$4.44 /

+0.42 (+10.45%)

, MRNA

Moderna

$176.85 /

+5.74 (+3.35%)

, U

Unity

$54.39 /

-4.17 (-7.12%)

, AGS

PlayAGS

$8.02 /

+0.505 (+6.72%)

, INSE

Inspired Entertainment

$12.01 /

-0.69 (-5.43%)

, POWW

AMMO

$5.38 /

-0.6 (-10.03%)

, SFT

Shift Technologies

$1.21 /

-0.03 (-2.42%)

, VRM

Vroom

$1.91 /

-0.21 (-9.93%)

, ITW

Illinois Tool Works

$213.78 /

-3.76 (-1.73%)

, POSH

Poshmark

$13.83 /

+2.04 (+17.31%)

, LLAP

Terran Orbital

$4.30 /

+0.045 (+1.06%)

, DG

Dollar General

$253.07 /

-0.19 (-0.08%)

, LU

Lufax

$4.02 /

+0.035 (+0.88%)

, BBLN

Babylon Holdings

/

+

, PTON

Peloton

$13.49 /

-0.03 (-0.22%)

, VRDN

Viridian Therapeutics

$22.00 /

+7.12 (+47.85%)

, TCRT

Alaunos Therapeutics

$1.96 /

+0.305 (+18.48%)

, TGB

Taseko Mines

$1.18 /

+0.09 (+8.26%)

, TRO

Trony Solar

/

+

, RIO

Rio Tinto

$58.48 /

-1.7 (-2.82%)

, HL

Hecla Mining

$4.48 /

-0.145 (-3.14%)

, TISI

Team

$1.54 /

+0.56 (+57.14%)

, LI

Li Auto

$32.66 /

+0.16 (+0.49%)

, YOU

Clear Secure

$28.46 /

-0.545 (-1.88%)

, IDYA

Ideaya Biosciences

$10.24 /

-5.48 (-34.86%)

, WEBR

Weber

$7.25 /

+0.34 (+4.92%)

, CAH

Cardinal Health

$70.03 /

+0.7 (+1.01%)

Get caught up quickly on…

ShowHide Related Items >><<
YOU Clear Secure
$28.46 /

-0.545 (-1.88%)

WMT Walmart
$132.59 /

+0.34 (+0.26%)

WEBR Weber
$7.25 /

+0.34 (+4.92%)

VRM Vroom
$1.91 /

-0.21 (-9.93%)

VRDN Viridian Therapeutics
$22.00 /

+7.12 (+47.85%)

U Unity
$54.39 /

-4.17 (-7.12%)

TISI Team
$1.54 /

+0.56 (+57.14%)

TGB Taseko Mines
$1.18 /

+0.09 (+8.26%)

TCRT Alaunos Therapeutics
$1.96 /

+0.305 (+18.48%)

SFT Shift Technologies
$1.21 /

-0.03 (-2.42%)

RIO Rio Tinto
$58.48 /

-1.7 (-2.82%)

PTON Peloton
$13.49 /

-0.03 (-0.22%)

POWW AMMO
$5.38 /

-0.6 (-10.03%)

POSH Poshmark
$13.83 /

+2.04 (+17.31%)

PARA Paramount
$26.57 /

+0.365 (+1.39%)

MRNA Moderna
$176.85 /

+5.74 (+3.35%)

LU Lufax
$4.02 /

+0.035 (+0.88%)

LLAP Terran Orbital
$4.30 /

+0.045 (+1.06%)

LI Li Auto
$32.66 /

+0.16 (+0.49%)

ITW Illinois Tool Works
$213.78 /

-3.76 (-1.73%)

IS ironSource
$4.44 /

+0.42 (+10.45%)

INSE Inspired Entertainment
$12.01 /

-0.69 (-5.43%)

IDYA Ideaya Biosciences
$10.24 /

-5.48 (-34.86%)

HL Hecla Mining
$4.48 /

-0.145 (-3.14%)

DIS Disney
$124.25 /

+2.695 (+2.22%)

DG Dollar General
$253.07 /

-0.19 (-0.08%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$40.55 /

+0.56 (+1.40%)

CAH Cardinal Health
$70.03 /

+0.7 (+1.01%)

BBLN Babylon Holdings
/

+

APP AppLovin
$33.45 /

-2.895 (-7.97%)

AGS PlayAGS
$8.02 /

+0.505 (+6.72%)

WMT Walmart
$132.59 /

+0.34 (+0.26%)

07/29/22 BofA
Amazon price target bumped to $170 at BofA after 'mostly positive' quarter
07/28/22 DA Davidson
Best Buy price target lowered to $88 from $110 at DA Davidson
07/28/22 Wells Fargo
Best Buy price target lowered to $70 from $82 at Wells Fargo
07/27/22 Deutsche Bank
Walmart price target lowered to $142 from $166 at Deutsche Bank
PARA Paramount
$26.57 /

+0.365 (+1.39%)

08/15/22 Benchmark
Nexstar getting 75% stake in CW Network for 'free,' says Benchmark
08/05/22 Deutsche Bank
Paramount price target lowered to $32 from $35 at Deutsche Bank
08/05/22 JPMorgan
JPMorgan downgrades Paramount to Underweight on soft DTC revenue
08/05/22 Morgan Stanley
Paramount price target lowered to $20 from $22 at Morgan Stanley
DIS Disney
$124.25 /

+2.695 (+2.22%)

08/11/22 Credit Suisse
Disney price target lowered to $157 from $170 at Credit Suisse
08/11/22 JPMorgan
Disney price target lowered to $160 from $175 at JPMorgan
08/11/22 KeyBanc
Disney price target raised to $154 from $131 at KeyBanc
08/11/22 Wells Fargo
Disney price target raised to $145 from $130 at Wells Fargo
CMCSA Comcast
$40.55 /

+0.56 (+1.40%)

08/15/22 Atlantic Equities
Comcast, Charter cut to Neutral at Atlantic Equities on broadband pressures
08/15/22 Atlantic Equities
Comcast downgraded to Neutral from Overweight at Atlantic Equities
08/10/22 RBC Capital
Disney price target lowered to $150 from $176 at RBC Capital
CMCSK Comcast
$58.00 /

+ (+0.00%)

07/20/22 KeyBanc
Disney price target lowered to $131 from $151 at KeyBanc
05/23/22 Raymond James
Electronic Arts moves 'somewhat unexpected,' says Raymond James
04/14/22 Oppenheimer
Comcast price target lowered to $60 from $75 at Oppenheimer
03/23/22 Craig-Hallum
ComScore poised for share gains in local measurement, says Craig-Hallum
APP AppLovin
$33.45 /

-2.895 (-7.97%)

08/12/22 DA Davidson
AppLovin price target lowered to $70 from $80 at DA Davidson
08/11/22 BTIG
AppLovin price target lowered to $53 from $60 at BTIG
08/11/22 Truist
AppLovin price target lowered to $65 from $77 at Truist
08/11/22 Credit Suisse
ironSource downgraded to Neutral from Outperform at Credit Suisse
IS ironSource
$4.44 /

+0.42 (+10.45%)

08/10/22 Citi
AppLovin bid for Unity faces 'several challenges,' says Citi
08/10/22 Barclays
Unity price target raised to $49 from $35 at Barclays
08/09/22 Stifel
Unity price target raised to $60 at Stifel after AppLovin proposal
MRNA Moderna
$176.85 /

+5.74 (+3.35%)

06/29/22 Evercore ISI
Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data
06/14/22 Piper Sandler
Piper Sandler confident in positive VRBPAC opinion for Moderna's SpikeVax
06/13/22 Morgan Stanley
Moderna pediatric EUA vaccine briefing docs 'clean,' says Morgan Stanley
05/17/22 Piper Sandler
Moderna price target lowered to $214 from $348 at Piper Sandler
U Unity
$54.39 /

-4.17 (-7.12%)

08/10/22 Oppenheimer
Unity price target raised to $60 from $54 at Oppenheimer
AGS PlayAGS
$8.02 /

+0.505 (+6.72%)

08/09/22 B. Riley
PlayAGS price target raised to $14 from $12 at B. Riley
08/01/22 Stifel
PlayAGS price target lowered to $9 from $11 at Stifel
07/20/22 Truist
PlayAGS price target lowered to $12 from $13 at Truist
07/14/22 Deutsche Bank
PlayAGS price target lowered to $11 from $12 at Deutsche Bank
INSE Inspired Entertainment
$12.01 /

-0.69 (-5.43%)

07/20/22 Truist
Inspired Entertainment price target lowered to $16 from $18 at Truist
07/14/22 B. Riley
Inspired Entertainment selloff a buying opportunity, says B. Riley
06/28/22 B. Riley
Inspired Entertainment price target lowered to $24 from $30 at B. Riley
06/03/22
Inspired Entertainment management to meet with Truist
POWW AMMO
$5.38 /

-0.6 (-10.03%)

06/30/22 EF Hutton
AMMO shares should be bought 'aggressively,' says EF Hutton
08/17/21 Lake Street
AMMO price target raised to $12 at Lake Street after beat and raise report
SFT Shift Technologies
$1.21 /

-0.03 (-2.42%)

08/15/22 JPMorgan
Shift Technologies downgraded to Underweight from Neutral at JPMorgan
08/15/22 JPMorgan
Shift Technologies downgraded to Underweight from Neutral at JPMorgan
08/10/22 DA Davidson
Shift Technologies downgraded to Neutral from Buy at DA Davidson
07/22/22 Cantor Fitzgerald
Shift Technologies assumed with an Overweight at Cantor Fitzgerald
VRM Vroom
$1.91 /

-0.21 (-9.93%)

08/15/22 JPMorgan
Vroom downgraded to Underweight from Neutral at JPMorgan
06/28/22 Stifel
Vroom price target lowered to $1.50 from $2 at Stifel
05/31/22 Truist
Vroom price target lowered to $2.60 from $4.00 at Truist
04/28/22 William Blair
William Blair downgrades Vroom on 'very rough start' to Q2
ITW Illinois Tool Works
$213.78 /

-3.76 (-1.73%)

08/15/22 Deutsche Bank
Illinois Tool Works downgraded to Sell at Deutsche Bank on valuation
08/15/22 Deutsche Bank
Illinois Tool Works downgraded to Sell from Hold at Deutsche Bank
08/03/22 Wells Fargo
Illinois Tool Works price target raised to $187 from $180 at Wells Fargo
08/03/22 Citi
Illinois Tool Works price target raised to $210 from $191 at Citi
POSH Poshmark
$13.83 /

+2.04 (+17.31%)

08/15/22 Barclays
Poshmark upgraded to Overweight from Equal Weight at Barclays
07/27/22 MKM Partners
MKM assumes Poshmark with Neutral rating, cites near-term profitability concerns
07/27/22 MKM Partners
Poshmark assumed with a Neutral at MKM Partners
06/29/22 Raymond James
Poshmark downgraded to Market Perform from Outperform at Raymond James
LLAP Terran Orbital
$4.30 /

+0.045 (+1.06%)

08/15/22 Stifel
Terran Orbital initiated with a Buy at Stifel
06/15/22 BofA
Terran Orbital initiated with Buy on government demand at BofA
06/15/22 BofA
Terran Orbital initiated with a Buy at BofA
05/16/22 Canaccord
Terran Orbital price target lowered to $18 from $22 at Canaccord
DG Dollar General
$253.07 /

-0.19 (-0.08%)

08/15/22 BMO Capital
Dollar General downgraded to Market Perform from Outperform at BMO Capital
08/10/22 Jefferies
Grocery Outlet price target raised to $45 from $30 at Jefferies
08/05/22 Truist
Dollar General price target raised to $262 from $227 at Truist
07/19/22 Oppenheimer
Dollar General price target raised to $275 from $240 at Oppenheimer
LU Lufax
$4.02 /

+0.035 (+0.88%)

08/05/22 CLSA
Lufax downgraded to Underperform from Outperform at CLSA
08/03/22 Citi
Citi opens '30-day negative Catalyst Watch' on Lufax into earnings
07/27/22 Daiwa
Lufax initiated with a Buy at Daiwa
05/27/22 CLSA
Lufax downgraded to Outperform from Buy at CLSA
BBLN Babylon Holdings
/

+

08/15/22 Citi
Babylon seeking buyer seems 'little bit' like 'wishful thinking,' says Citi
06/23/22 BofA
Babylon Holdings initiated with a Neutral at BofA
05/16/22 Canaccord
Babylon Holdings price target lowered to $5 from $8 at Canaccord
05/13/22 Citi
Babylon Holdings price target lowered to $1.50 from $5 at Citi
PTON Peloton
$13.49 /

-0.03 (-0.22%)

07/22/22 Oppenheimer
Peloton assumed with an Outperform at Oppenheimer
07/22/22 Piper Sandler
Peloton initiated with a Neutral at Piper Sandler
07/13/22 JMP Securities
Peloton still has long runway for growth, says JMP Securities
06/29/22 JPMorgan
Peloton price target lowered to $20 from $24 at JPMorgan
VRDN Viridian Therapeutics
$22.00 /

+7.12 (+47.85%)

08/15/22 Evercore ISI
Viridian Therapeutics price target raised to $50 from $40 at Evercore ISI
06/23/22 B. Riley
B. Riley starts Viridian Therapeutics at Buy with $25 price target
06/23/22 B. Riley
Viridian Therapeutics initiated with a Buy at B. Riley
11/18/21 SVB Securities
Viridian Therapeutics initiated with an Outperform at SVB Leerink
TCRT Alaunos Therapeutics
$1.96 /

+0.305 (+18.48%)

07/15/22 Cantor Fitzgerald
Alaunos Therapeutics assumed with an Overweight at Cantor Fitzgerald
05/04/22 Wells Fargo
Wells Fargo upgrades Alaunos Therapeutics to Overweight with $3 price target
05/04/22 Wells Fargo
Alaunos upgraded to Overweight from Equal Weight at Wells Fargo
TGB Taseko Mines
$1.18 /

+0.09 (+8.26%)

08/10/22 Scotiabank
Taseko Mines price target lowered to C$1.75 from C$2 at Scotiabank
08/10/22 TD Securities
Taseko Mines price target lowered to C$2.25 from C$2.50 at TD Securities
08/09/22 BMO Capital
Taseko Mines price target lowered to C$2.50 from C$2.75 at BMO Capital
07/19/22 Stifel
Taseko Mines price target lowered to C$2.50 from C$3.40 at Stifel
TRO Trony Solar
/

+

RIO Rio Tinto
$58.48 /

-1.7 (-2.82%)

07/29/22 Berenberg
Rio Tinto price target raised to 4,300 GBp from 4,100 GBp at Berenberg
07/28/22 JPMorgan
Rio Tinto price target raised to 5,350 GBp from 5,300 GBp at JPMorgan
07/28/22 UBS
Rio Tinto price target lowered to 4,300 GBp from 4,400 GBp at UBS
07/28/22 RBC Capital
Rio Tinto price target lowered to 4,700 GBp from 4,900 GBp at RBC Capital
HL Hecla Mining
$4.48 /

-0.145 (-3.14%)

07/26/22 H.C. Wainwright
Hecla Mining price target lowered to $6.50 from $8.25 at H.C. Wainwright
07/06/22 Canaccord
Hecla Mining price target lowered to $3.50 from $5.00 at Canaccord
05/11/22 B. Riley
Hecla Mining price target lowered to $9 from $11 at B. Riley
05/11/22 Roth Capital
Roth Capital upgrades Hecla Mining to Buy, lowers price target to $6.25
TISI Team
$1.54 /

+0.56 (+57.14%)

LI Li Auto
$32.66 /

+0.16 (+0.49%)

08/08/22 CLSA
Li Auto initiated with a Buy at CLSA
06/29/22 Morgan Stanley
Li Auto capital replenishment a strategic positive, says Morgan Stanley
06/21/22 Citi
Li Auto price target raised to $58.60 from $26.80 at Citi
05/11/22 Citi
Li Auto price target lowered to $26.80 from $51.50 at Citi
YOU Clear Secure
$28.46 /

-0.545 (-1.88%)

06/14/22 JPMorgan
JPMorgan 'incrementally constructive' on Clear Secure after U.S. survey
03/30/22 Loop Capital
Clear Secure price target lowered to $26 from $40 at Loop Capital
03/23/22 Stifel
Clear Secure price target raised to $34 from $32 at Stifel
03/15/22 Wells Fargo
Clear Secure price target lowered to $21 from $29 at Wells Fargo
IDYA Ideaya Biosciences
$10.24 /

-5.48 (-34.86%)

08/16/22 Oppenheimer
Ideaya Biosciences price target lowered to $20 from $25 at Oppenheimer
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold at Stifel after GSK waives IDE397 opt-in
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold from Buy at Stifel
07/15/22 Oppenheimer
Ideaya Biosciences assumed with an Outperform at Oppenheimer
WEBR Weber
$7.25 /

+0.34 (+4.92%)

08/02/22 Citi
Weber transferred with Neutral rating at Citi
08/01/22 UBS
Weber downgraded to Sell from Neutral at UBS
07/28/22 Citi
Weber price target lowered to $7 from $8 at Citi
07/26/22 Wells Fargo
Wells Fargo downgrades Weber to Underweight, lowers price target to $4
CAH Cardinal Health
$70.03 /

+0.7 (+1.01%)

08/12/22 Mizuho
Cardinal Health price target raised to $66 from $58 at Mizuho
08/11/22 Baird
Cardinal Health price target raised to $73 from $57 at Baird
07/14/22 Morgan Stanley
Cardinal Health price target lowered to $70 from $74 at Morgan Stanley
05/26/22 Barclays
Cardinal Health downgraded to Equal Weight from Overweight at Barclays
YOU Clear Secure
$28.46 /

-0.545 (-1.88%)

WMT Walmart
$132.59 /

+0.34 (+0.26%)

WEBR Weber
$7.25 /

+0.34 (+4.92%)

VRM Vroom
$1.91 /

-0.21 (-9.93%)

VRDN Viridian Therapeutics
$22.00 /

+7.12 (+47.85%)

U Unity
$54.39 /

-4.17 (-7.12%)

TISI Team
$1.54 /

+0.56 (+57.14%)

TCRT Alaunos Therapeutics
$1.96 /

+0.305 (+18.48%)

SFT Shift Technologies
$1.21 /

-0.03 (-2.42%)

PTON Peloton
$13.49 /

-0.03 (-0.22%)

POWW AMMO
$5.38 /

-0.6 (-10.03%)

POSH Poshmark
$13.83 /

+2.04 (+17.31%)

PARA Paramount
$26.57 /

+0.365 (+1.39%)

MRNA Moderna
$176.85 /

+5.74 (+3.35%)

LU Lufax
$4.02 /

+0.035 (+0.88%)

LI Li Auto
$32.66 /

+0.16 (+0.49%)

ITW Illinois Tool Works
$213.78 /

-3.76 (-1.73%)

IS ironSource
$4.44 /

+0.42 (+10.45%)

INSE Inspired Entertainment
$12.01 /

-0.69 (-5.43%)

IDYA Ideaya Biosciences
$10.24 /

-5.48 (-34.86%)

HL Hecla Mining
$4.48 /

-0.145 (-3.14%)

DIS Disney
$124.25 /

+2.695 (+2.22%)

DG Dollar General
$253.07 /

-0.19 (-0.08%)

CMCSA Comcast
$40.55 /

+0.56 (+1.40%)

CAH Cardinal Health
$70.03 /

+0.7 (+1.01%)

BBLN Babylon Holdings
/

+

APP AppLovin
$33.45 /

-2.895 (-7.97%)

AGS PlayAGS
$8.02 /

+0.505 (+6.72%)

  • 03
    Dec
  • 16
    Nov
  • 21
    Sep
WMT Walmart
$132.59 /

+0.34 (+0.26%)

WEBR Weber
$7.25 /

+0.34 (+4.92%)

U Unity
$54.39 /

-4.17 (-7.12%)

RIO Rio Tinto
$58.48 /

-1.7 (-2.82%)

PTON Peloton
$13.49 /

-0.03 (-0.22%)

POSH Poshmark
$13.83 /

+2.04 (+17.31%)

PARA Paramount
$26.57 /

+0.365 (+1.39%)

MRNA Moderna
$176.85 /

+5.74 (+3.35%)

LU Lufax
$4.02 /

+0.035 (+0.88%)

LI Li Auto
$32.66 /

+0.16 (+0.49%)

DIS Disney
$124.25 /

+2.695 (+2.22%)

DG Dollar General
$253.07 /

-0.19 (-0.08%)

CMCSA Comcast
$40.55 /

+0.56 (+1.40%)

CAH Cardinal Health
$70.03 /

+0.7 (+1.01%)

BBLN Babylon Holdings
/

+

APP AppLovin
$33.45 /

-2.895 (-7.97%)

AGS PlayAGS
$8.02 /

+0.505 (+6.72%)

YOU Clear Secure
$28.46 /

-0.545 (-1.88%)

WMT Walmart
$132.59 /

+0.34 (+0.26%)

WEBR Weber
$7.25 /

+0.34 (+4.92%)

VRM Vroom
$1.91 /

-0.21 (-9.93%)

U Unity
$54.39 /

-4.17 (-7.12%)

TCRT Alaunos Therapeutics
$1.96 /

+0.305 (+18.48%)

SFT Shift Technologies
$1.21 /

-0.03 (-2.42%)

RIO Rio Tinto
$58.48 /

-1.7 (-2.82%)

PTON Peloton
$13.49 /

-0.03 (-0.22%)

POWW AMMO
$5.38 /

-0.6 (-10.03%)

POSH Poshmark
$13.83 /

+2.04 (+17.31%)

PARA Paramount
$26.57 /

+0.365 (+1.39%)

MRNA Moderna
$176.85 /

+5.74 (+3.35%)

LLAP Terran Orbital
$4.30 /

+0.045 (+1.06%)

LI Li Auto
$32.66 /

+0.16 (+0.49%)

ITW Illinois Tool Works
$213.78 /

-3.76 (-1.73%)

IS ironSource
$4.44 /

+0.42 (+10.45%)

INSE Inspired Entertainment
$12.01 /

-0.69 (-5.43%)

HL Hecla Mining
$4.48 /

-0.145 (-3.14%)

DIS Disney
$124.25 /

+2.695 (+2.22%)

DG Dollar General
$253.07 /

-0.19 (-0.08%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CAH Cardinal Health
$70.03 /

+0.7 (+1.01%)

BBLN Babylon Holdings
/

+

APP AppLovin
$33.45 /

-2.895 (-7.97%)

AGS PlayAGS
$8.02 /

+0.505 (+6.72%)

WMT Walmart
$132.59 /

+0.34 (+0.26%)

WEBR Weber
$7.25 /

+0.34 (+4.92%)

VRM Vroom
$1.91 /

-0.21 (-9.93%)

U Unity
$54.39 /

-4.17 (-7.12%)

TGB Taseko Mines
$1.18 /

+0.09 (+8.26%)

TCRT Alaunos Therapeutics
$1.96 /

+0.305 (+18.48%)

SFT Shift Technologies
$1.21 /

-0.03 (-2.42%)

RIO Rio Tinto
$58.48 /

-1.7 (-2.82%)

PTON Peloton
$13.49 /

-0.03 (-0.22%)

POWW AMMO
$5.38 /

-0.6 (-10.03%)

POSH Poshmark
$13.83 /

+2.04 (+17.31%)

PARA Paramount
$26.57 /

+0.365 (+1.39%)

MRNA Moderna
$176.85 /

+5.74 (+3.35%)

LU Lufax
$4.02 /

+0.035 (+0.88%)

LLAP Terran Orbital
$4.30 /

+0.045 (+1.06%)

LI Li Auto
$32.66 /

+0.16 (+0.49%)

HL Hecla Mining
$4.48 /

-0.145 (-3.14%)

DIS Disney
$124.25 /

+2.695 (+2.22%)

DG Dollar General
$253.07 /

-0.19 (-0.08%)

CMCSA Comcast
$40.55 /

+0.56 (+1.40%)

CAH Cardinal Health
$70.03 /

+0.7 (+1.01%)

APP AppLovin
$33.45 /

-2.895 (-7.97%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.